Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARC-LI: TMS + NRX-101 in Major Depression
NCT07785102Phase 1Recruiting
- Sponsor
- McLean Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of d-cycloserine + lurasidone in major depressive disorder (MDD), sponsored by McLean Hospital. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 6 weeks. Started Oct 2026; status: recruiting.
02
Drugs
d-cycloserine + lurasidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07785102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07785102.